Nasdaq
$1.58▼ 0.32%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $248.1MShares out 1.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 3d agoAfter-hours26.10.22 05:104Ownership#●●●
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics executive Scott M. Wasserman filed a Form 4 on October 21, 2026, reporting a change in beneficial ownership of securities as of October 19, 2026. This filing serves as the official disclosure of the insider's equity transaction.…more
$1.58-0.32%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 05:053Ownership
Inhibikase Therapeutics, Inc.
Scott Wasserman of Inhibikase Therapeutics has filed a Power of Attorney authorizing Mark Iwicki and David McIntyre to handle SEC reporting requirements on his behalf. This is an administrative filing granting them the authority to prepare and submit necessary securities transaction reports.…more
$1.58-0.32%vs prev closeView filingShare - 4d agoAfter-hours26.10.21 05:578-KKey event
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics announced the resignation of director Dennis Berman and the appointment of Dr. Scott Wasserman to its Board of Directors, effective October 19, 2026. Dr. Wasserman was granted stock options to purchase up to 310,000 shares, and the company intends to leverage his expertise to advance the ongoing Phase 3 IMPROVE-PAH study of IKT-001.…more
$1.58-0.32%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoAfter-hours26.10.21 05:01#●●●#●●●
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
Inhibikase Therapeutics has appointed clinical expert Dr. Scott Wasserman to its Board of Directors. This move is intended to bolster the company's ongoing Phase 3 clinical trial for its pulmonary arterial hypertension treatment, IKT-001.…more
$1.58-0.32%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.2After-hours26.10.03 05:01
●●●●●●●● ●●●●● ●●●●●●
Inhibikase Therapeutics has granted stock options for up to 128,000 shares to two newly hired employees as an employment inducement. This grant is part of the company's equity plan and does not represent a material financial event for shareholders.…more
$1.58-0.32%vs prev close - 8.11After-hours26.08.12 05:01
●●●●●●●● ●●●●● ●●●●●●
인히비케이스는 폐동맥고혈압 치료제 IKT-001의 글로벌 임상 3상을 26개국에서 진행하며 순조롭게 개발 중이라고 밝혔다. 최근 5천만 달러 규모의 자금 조달을 완료하며 임상 데이터 확보를 위한 운영 자금을 안정적으로 확보했다.…more
$1.58-0.32%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report